Get the Stockscreener App
10.03
1.18%
-0.12
After Hours:
10.12
0.09
+0.90%
Ars Pharmaceuticals Inc stock is traded at $10.03, with a volume of 2.27M.
It is down -1.18% in the last 24 hours and down -39.80% over the past month.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
See More
Previous Close:
$10.15
Open:
$10.1
24h Volume:
2.27M
Relative Volume:
1.15
Market Cap:
$991.23M
Revenue:
-
Net Income/Loss:
$-44.84M
P/E Ratio:
-21.34
EPS:
-0.47
Net Cash Flow:
$-44.23M
1W Performance:
-0.40%
1M Performance:
-39.80%
6M Performance:
-18.52%
1Y Performance:
-20.59%
1-Day Range:
$9.79
$10.17
1-Week Range:
$9.79
$10.78
52-Week Range:
$9.79
$18.90
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Name
Ars Pharmaceuticals Inc
Sector
Industry
Phone
858-771-9307
Address
11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
Compare SPRY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
10.03 | 1.04B | 0 | -44.84M | -44.23M | -0.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Initiated | Roth Capital | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-10-25 | Initiated | Oppenheimer | Outperform |
| Aug-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-12-24 | Reiterated | Leerink Partners | Outperform |
| Jul-25-24 | Initiated | Raymond James | Outperform |
| Mar-05-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-20-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Sep-20-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-31-23 | Initiated | Wedbush | Outperform |
| Jan-03-23 | Initiated | William Blair | Outperform |
| Dec-13-22 | Initiated | SVB Leerink | Outperform |
View All
Ars Pharmaceuticals Inc Stock (SPRY) Latest News
Research Analysts Issue Forecasts for SPRY Q3 Earnings - MarketBeat
Alliancebernstein L.P. Acquires 42,071 Shares of ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
Octagon Capital Advisors LP Makes New $7.86 Million Investment in ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
ARS Pharmaceuticals, Inc. $SPRY Shares Purchased by Trexquant Investment LP - MarketBeat
ARS Pharmaceuticals (NASDAQ:SPRY) Sets New 1-Year LowTime to Sell? - MarketBeat
Ars Pharmaceuticals Reports Strong Q2 Growth and Global Expansion - MSN
Alyeska Investment Group L.P. Reduces Stock Position in ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
Cormorant Asset Management LP Acquires 1,100,000 Shares of ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
Neffy demonstrates positive, real-world data for anaphylaxis - Contemporary Pediatrics
Is ARS Pharmaceuticals Inc. attractive at current valuation2025 Growth vs Value & Fast Entry and Exit Trade Plans - Lancaster City Council
ARS Pharmaceuticals announces real-world evidence on neffy effectiveness - Yahoo Finance
Roth Capital Begins Coverage on ARS Pharmaceuticals (NASDAQ:SPRY) - MarketBeat
Real-World Evidence Supports Clinical Effectiveness of neffy® (epinephrine nasal spray) in Patients Experiencing Anaphylaxis - markets.businessinsider.com
Real-World Evidence Supports Clinical Effectiveness of - GlobeNewswire
89% Success Rate: Revolutionary Nasal Spray neffy Matches Standard Injection for Life-Threatening Allergies - Stock Titan
Published on: 2025-09-08 12:54:11 - beatles.ru
AI Trend Models Suggest Bounce for ARS Pharmaceuticals Inc.2025 Market Trends & AI Driven Stock Price Forecasts - beatles.ru
325,000 Shares in ARS Pharmaceuticals, Inc. $SPRY Purchased by Ardsley Advisory Partners LP - MarketBeat
ARS Pharmaceuticals (SPRY) Faces Patent Test as Lupin Files ANDA - MSN
What moving averages say about ARS Pharmaceuticals Inc.Weekly Stock Report & Consistent Return Investment Signals - Newser
MPM Bioimpact LLC Makes New $16.52 Million Investment in ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
Will ARS Pharmaceuticals' (SPRY) Conference Outreach Shape Investor Expectations for neffy's Global Potential? - simplywall.st
Is it too late to sell ARS Pharmaceuticals Inc.July 2025 PostEarnings & AI Driven Stock Price Forecasts - Newser
ARS Pharmaceuticals, Inc. $SPRY Shares Sold by Rafferty Asset Management LLC - MarketBeat
What’s the outlook for ARS Pharmaceuticals Inc.’s sectorQuarterly Market Review & Risk Controlled Stock Pick Alerts - خودرو بانک
Using economic indicators to assess ARS Pharmaceuticals Inc. potentialJuly 2025 Levels & Real-Time Stock Entry Alerts - Newser
ARS Pharmaceuticals stock hits 52-week low at 9.97 USD By Investing.com - Investing.com Canada
What is ARS Pharmaceuticals Inc. s debt to equity ratio2025 Sector Review & Growth Focused Investment Plans - خودرو بانک
What drives ARS Pharmaceuticals Inc.’s stock priceTrade Performance Summary & Reliable Price Breakout Signals - خودرو بانک
Key resistance and support levels for ARS Pharmaceuticals Inc.Earnings Growth Summary & Safe Entry Trade Signal Reports - Newser
Price momentum metrics for ARS Pharmaceuticals Inc. explainedJuly 2025 Setups & Expert Curated Trade Setups - Newser
ARS Pharmaceuticals stock hits 52-week low at 9.97 USD - Investing.com
Is ARS Pharmaceuticals Inc. backed by strong institutional buyingEarnings Recap Summary & Daily Technical Stock Forecast Reports - خودرو بانک
Analysts Offer Insights on Healthcare Companies: Novan (NOVN) and ARS Pharmaceuticals (SPRY) - The Globe and Mail
Intraday pattern recognizer results for ARS Pharmaceuticals Inc.2025 Trade Ideas & Real-Time Stock Price Movement Reports - Newser
Chart overlay techniques for tracking ARS Pharmaceuticals Inc.Global Markets & Real-Time Buy Zone Alerts - Newser
Raymond James Financial Inc. Has $8.89 Million Holdings in ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
Comparing ARS Pharmaceuticals Inc. in custom built stock radarsMarket Risk Report & Risk Managed Investment Strategies - Newser
When is the best time to exit ARS Pharmaceuticals Inc.Portfolio Update Report & Stepwise Entry/Exit Trade Alerts - Newser
Is ARS Pharmaceuticals Inc. forming a bottoming basePortfolio Value Summary & Daily Entry Point Alerts - Newser
What recovery options are there for ARS Pharmaceuticals Inc.Trade Performance Summary & Community Verified Watchlist Alerts - Newser
What are the risks of holding ARS Pharmaceuticals Inc.2025 Bull vs Bear & Free Accurate Trade Setup Notifications - خودرو بانک
What are ARS Pharmaceuticals Inc.’s earnings expectationsJuly 2025 Trends & Low Drawdown Momentum Trade Ideas - خودرو بانک
Roth/MKM initiates ARS Pharmaceuticals stock with Buy rating on neffy potential - Investing.com
What are ARS Pharmaceuticals Inc.’s growth leversJuly 2025 Snapshot & Verified Momentum Stock Watchlist - خودرو بانک
Short Squeeze: How does ARS Pharmaceuticals Inc. compare to its peersWeekly Trade Summary & Breakout Confirmation Trade Signals - خودرو بانک
ARS Pharmaceuticals, Inc.'s (NASDAQ:SPRY) 27% Share Price Plunge Could Signal Some Risk - 富途牛牛
What machine learning models say about ARS Pharmaceuticals Inc.July 2025 Movers & Safe Capital Investment Plans - Newser
Kodai Capital Management LP Acquires Shares of 60,111 ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
Using data models to predict ARS Pharmaceuticals Inc. stock movementGap Up & Community Shared Stock Ideas - Newser
Applying Elliott Wave Theory to ARS Pharmaceuticals Inc.Rate Hike & Breakout Confirmation Alerts - Newser
Ars Pharmaceuticals Inc Stock (SPRY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):